Record-Breaking Price Movement
The stock of Fredun Pharmaceuticals Ltd surged to an intraday high of Rs 1,329.90, marking a 4.22% increase on the day and closing near its 52-week high of Rs 1,331.70, just 0.61% shy of that peak. The day’s performance outpaced the Pharmaceuticals & Biotechnology sector by 4.13% and the broader Sensex index, which declined by 0.69%. This marks the second consecutive day of gains, with the stock appreciating 8.67% over this period.
Trading above all major moving averages—including the 5-day, 20-day, 50-day, 100-day, and 200-day—Fredun Pharmaceuticals demonstrates a robust bullish trend that has been in place since early April 2026, when the trend shifted from mildly bullish to firmly bullish at a price of Rs 611.58.
Exceptional Long-Term and Short-Term Performance
Fredun Pharmaceuticals has delivered remarkable returns over multiple time horizons. The stock’s one-year return stands at an impressive 291.75%, vastly outperforming the Sensex’s negative 3.27% return over the same period. Year-to-date, the stock has gained 155.27%, while the Sensex has declined by 8.93%. Over three years, the stock has appreciated by 297.95%, compared to the Sensex’s 18.81% gain, and over five years, it has surged by an extraordinary 921.91%, dwarfing the Sensex’s 41.51% increase.
Shorter-term performance also highlights strength, with a 55.96% gain over the past month and 70.65% over three months, compared to the Sensex’s near flat or modest positive returns. This consistent outperformance underscores the company’s ability to generate value across market cycles.
Strong Financial Fundamentals Underpinning Growth
Fredun Pharmaceuticals’ financial results for June 2026 quarter were outstanding, with net sales reaching a record ₹228.25 crores and operating cash flow for the year hitting a high of ₹16.44 crores. Operating profit to interest coverage ratio also peaked at 3.80 times, reflecting improved earnings quality and debt servicing capacity.
The company reported a net profit growth of 94.53% in the latest quarter, continuing a streak of positive results for nine consecutive quarters. Quarterly profit after tax stood at ₹13.13 crores, while profit before tax excluding other income reached ₹20.55 crores, both at their highest levels to date.
Valuation and Quality Metrics
Despite the strong price appreciation, Fredun Pharmaceuticals trades at a price-to-earnings ratio of 48x (TTM), with a price-to-book value of 7.57x and an EV/EBITDA multiple of 20.50x. The enterprise value to capital employed ratio is 5.20x, indicating a fair valuation relative to its capital base. The PEG ratio of 0.76x suggests that the stock’s price growth is supported by earnings growth, which has risen by 89.6% over the past year.
The company’s return on capital employed (ROCE) stands at a healthy 19.9%, signalling efficient utilisation of capital. Dividend yield remains modest at 0.03%, with a payout ratio of 1.15%, reflecting a focus on reinvestment for growth.
Quality Assessment and Risk Profile
Fredun Pharmaceuticals is classified as an average quality company based on long-term financial performance. It boasts excellent growth metrics, with a five-year sales compound annual growth rate (CAGR) of 34.99% and EBIT growth of 62.66%. However, capital structure metrics indicate moderate leverage, with an average debt-to-EBITDA ratio of 2.93 and net debt-to-equity of 0.56.
Management risk is assessed as average, and the company maintains a low promoter share pledge at 0.0%. Institutional holdings are relatively low at 4.00%. The average return on equity (ROE) is weaker at 12.48%, while the average EBIT to interest coverage ratio is 2.59x, indicating some room for improvement in interest coverage over the long term.
Technical Indicators and Market Behaviour
Technical analysis confirms a bullish trend, supported by positive signals from MACD, Bollinger Bands, and KST indicators on both weekly and monthly timeframes. The relative strength index (RSI) shows a bearish signal on the weekly chart but no signal on the monthly chart, suggesting some short-term caution amid the broader upward momentum.
Delivery volumes have surged, with a 1-month delivery change of 261.34% and a 1-day delivery change of 65.62% compared to the 5-day average, indicating strong market participation in recent trading sessions.
Summary of Key Financial and Market Metrics
Fredun Pharmaceuticals Ltd’s market capitalisation is classified as micro-cap, yet it has demonstrated market-beating performance across multiple periods. The stock’s recent upgrade from a Hold to a Strong Buy rating by MarketsMOJO on 31 July 2026 reflects the company’s improved fundamentals and growth prospects. The Mojo Score stands at 80.0, underscoring the stock’s strong investment appeal based on quantitative analysis.
Overall, the achievement of an all-time high price is a testament to Fredun Pharmaceuticals’ sustained financial strength, operational excellence, and market confidence, marking a significant milestone in the company’s growth journey.
